Business
Immunic to Participate in Scientific and Industry Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May:
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May:","length":327,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"May 3-6: Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in San Diego, CA.","length":340,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster Title: IMU-856 vs. Placebo Efficacy Effects in Celiac Disease Patients Are Independent of Q-MARSH Scale at Baseline","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract ID: 4216653","length":25,"tagName":"p"}]},{"val":[{"type":"text","content":"Poster Number: Tu1329","length":26,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting Author: Indira Pichetto Olanda, M.D., Associate Medical Manager, Immunic","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Enteropathies — Celiac, Gluten Related and Environmental","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Date: Tuesday, May 6, 2025","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Time: 12:30 – 1:30 pm PDT","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Poster Title: Influence of Gut Epithelial Condition on the Pharmacokinetic Properties of IMU-856, an Oral Regulator of Barrier Function for the Treatment of Celiac Disease","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract ID: 4219364","length":25,"tagName":"p"}]},{"val":[{"type":"text","content":"Poster Number: Tu1344","length":26,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting Author: Jacques Arend, M.D., Head of Clinical Pharmacology, Immunic","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Enteropathies — Celiac, Gluten Related and Environmental","length":70,"ta...